Spyre Therapeutics, Inc. - Common Stock (SYRE)
CUSIP: 00773J202
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 78,841,667
- Total 13F shares
- 667
- Share change
- +230
- Total reported value
- $33,530
- Price per share
- $50.44
- Number of holders
- 3
- Value change
- +$11,545
- Number of buys
- 2
Quarterly Holders Quick Answers
What is CUSIP 00773J202?
CUSIP 00773J202 identifies SYRE - Spyre Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Previous quarter: Q4 2025
Recent filing periods for CUSIP 00773J202:
Top shareholders of SYRE - Spyre Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
|
Company |
15%
|
11,638,819
|
$381,287,711 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
6.6%
from 13D/G
|
5,522,101
|
$180,904,030 | — | 31 Dec 2025 | |
| RTW INVESTMENTS, LP |
13F
13D/G
|
Company |
6.2%
from 13D/G
|
4,171,996
|
$136,674,589 | — | 31 Dec 2025 | |
| Fairmount Funds Management LLC |
13D/G
3/4/5
13F
|
Peter Evan Harwin · Director · Company |
10%
|
8,106,882
|
$136,033,480 | $0 | 15 Oct 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
5.1%
|
4,035,074
|
$132,189,024 | — | 31 Dec 2025 | |
| VR Adviser, LLC |
13F
|
Company |
4.7%
|
3,685,448
|
$120,735,276 | — | 31 Dec 2025 | |
| Capital International Investors |
13F
|
Company |
4.4%
|
3,492,541
|
$114,415,643 | — | 31 Dec 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
13D/G
|
Company |
4.4%
from 13D/G
|
3,069,225
|
$100,547,811 | — | 31 Dec 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
3.7%
|
2,882,420
|
$94,428,079 | — | 31 Dec 2025 | |
| Commodore Capital LP |
13F
|
Company |
3%
|
2,388,245
|
$78,238,906 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.9%
|
2,262,839
|
$74,130,606 | — | 31 Dec 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
2.4%
|
1,900,582
|
$62,263,066 | — | 31 Dec 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13D/G
13F
|
Company |
2.4%
|
1,892,200
|
$62,064,160 | -$42,895,840 | 31 Dec 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
2.3%
|
1,829,009
|
$59,918,335 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.1%
|
1,659,140
|
$54,362,088 | — | 31 Dec 2025 | |
| BRAIDWELL LP |
13F
|
Company |
2.1%
|
1,634,615
|
$53,549,987 | — | 31 Dec 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
2.1%
|
1,621,620
|
$53,124,271 | — | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
2%
|
1,601,882
|
$52,479,000 | — | 31 Dec 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
2%
|
1,549,284
|
$50,754,544 | — | 31 Dec 2025 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
1.9%
|
1,467,266
|
$48,067,634 | — | 31 Dec 2025 | |
| Remedium Capital Partners, LLC |
13F
|
Company |
1.8%
|
1,456,231
|
$47,706,000 | — | 31 Dec 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
1.8%
|
1,432,591
|
$46,931,681 | — | 31 Dec 2025 | |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
— |
4.6%
|
2,685,448
|
$40,335,429 | $0 | 31 Dec 2024 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
1.4%
|
1,109,274
|
$36,339,817 | — | 31 Dec 2025 | |
| BAKER BROS. ADVISORS LP |
13F
3/4/5
|
Company · Director |
1.3%
|
1,000,000
|
$32,760,000 | — | 31 Dec 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
1.2%
|
913,960
|
$29,941,330 | — | 31 Dec 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
1%
|
818,598
|
$26,817,270 | — | 31 Dec 2025 | |
| Polar Capital Holdings Plc |
13F
|
Company |
0.94%
|
740,326
|
$24,253,080 | — | 31 Dec 2025 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
0.9%
|
710,626
|
$23,280,108 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.86%
|
680,566
|
$22,295,342 | — | 31 Dec 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.84%
|
662,351
|
$21,698,619 | — | 31 Dec 2025 | |
| EMERALD ADVISERS, LLC |
13F
|
Company |
0.81%
|
636,109
|
$20,838,931 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.73%
|
574,622
|
$18,824,617 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.71%
|
561,023
|
$18,379,115 | — | 31 Dec 2025 | |
| Blackstone Inc. |
13F
|
Company |
0.64%
|
500,998
|
$16,412,694 | — | 31 Dec 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.54%
|
425,534
|
$13,941,087 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.53%
|
419,727
|
$13,750,257 | — | 31 Dec 2025 | |
| EMERALD MUTUAL FUND ADVISERS TRUST |
13F
|
Company |
0.52%
|
412,371
|
$13,509,274 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.35%
|
275,065
|
$9,011,129 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.34%
|
265,892
|
$8,710,622 | — | 31 Dec 2025 | |
| Capital World Investors |
13F
|
Company |
0.25%
|
200,172
|
$6,557,635 | — | 31 Dec 2025 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
0.25%
|
196,426
|
$6,434,916 | — | 31 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.24%
|
192,830
|
$6,317,104 | — | 31 Dec 2025 | |
| HighVista Strategies LLC |
13F
|
Company |
0.24%
|
188,206
|
$6,165,629 | — | 31 Dec 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.24%
|
187,737
|
$6,150,264 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.23%
|
182,734
|
$5,986,378 | — | 31 Dec 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.23%
|
182,524
|
$5,979,487 | — | 31 Dec 2025 | |
| Universal- Beteiligungs- und Servicegesellschaft mbH |
13F
|
Individual |
0.22%
|
171,211
|
$5,608,873 | — | 31 Dec 2025 | |
| Michael Thomas Henderson |
3/4/5
|
Director |
—
mixed-class rows
|
193,606
mixed-class rows
|
$5,523,583 | — | 21 Jan 2026 | |
| Nuveen, LLC |
13F
|
Company |
0.19%
|
150,980
|
$4,946,105 | — | 31 Dec 2025 |
Institutional Holders of Spyre Therapeutics, Inc. - Common Stock (SYRE) as of Q1 2026
As of 31 Mar 2026,
Spyre Therapeutics, Inc. - Common Stock (SYRE) was held by
3 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
667 shares.
The largest 3 holders included
GAMMA Investing LLC, Farther Finance Advisors, LLC, and SIGNATUREFD, LLC.
This page lists
3
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
152
Q1 2026 holders
3
Holder diff
-149
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.